Related Experiment Video
Updated: Jul 21, 2026

Mouse Models of Periventricular Leukomalacia
Published on: May 18, 2010
Pediatric inflammatory leukoencephalopathies
Omar Abdel-Mannan1, Yael Hacohen1
1Department of Neuroinflammation, Queen Square MS Centre, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, United Kingdom; Department of Neurology, Great Ormond Street Hospital, London, United Kingdom.
Insights
Acquired demyelinating syndromes (ADS) in children, including multiple sclerosis (MS), are distinct from myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and aquaporin 4-antibody-positive neuromyelitis optica spectrum disorder (AQP4-NMOSD). Differentiating these conditions is crucial for effective treatment strategies.
Area of Science:
- Pediatric Neurology
- Neuroimmunology
- Demyelinating Diseases
Background:
- Acquired demyelinating syndromes (ADS) are acute neurological conditions affecting the optic nerve, brain, or spinal cord in children.
- While multiple sclerosis (MS) is a common relapsing form of ADS, other distinct entities like myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and aquaporin 4-antibody-positive neuromyelitis optica spectrum disorder (AQP4-NMOSD) have been identified.
- Historically considered variants of MS, MOGAD and AQP4-NMOSD are now recognized as separate conditions based on cumulative evidence.
Purpose of the Study:
- To delineate distinct subtypes of acquired demyelinating syndromes (ADS) in pediatric patients.
- To highlight the differences between multiple sclerosis (MS), MOGAD, and AQP4-NMOSD despite clinical overlaps.
- To emphasize the importance of accurate diagnosis for guiding treatment in pediatric ADS.
Main Methods:
- Review of clinical, biologic, and pathologic evidence differentiating MS, MOGAD, and AQP4-NMOSD.
- Analysis of diagnostic criteria and phenotypic characteristics of pediatric ADS.
- Examination of current and emerging therapeutic approaches for these distinct conditions.
Main Results:
- Biologic, clinical, and pathologic data confirm MOGAD and AQP4-NMOSD as distinct entities from MS.
- Phenotypic overlaps exist but do not preclude differentiation between MS, MOGAD, and AQP4-NMOSD.
- Numerous inflammatory and non-inflammatory conditions can mimic ADS in children, necessitating careful diagnosis.
Conclusions:
- Accurate discrimination between pediatric MS, MOGAD, and AQP4-NMOSD is essential for appropriate patient management.
- Advances in disease-modifying therapies for MS and emerging treatments for MOGAD and AQP4-NMOSD underscore the need for precise diagnosis.
- Recognizing mimics of ADS is critical for effective treatment planning in pediatric neurological care.
Abstract:
Acquired demyelinating syndromes (ADS) represent acute neurologic illnesses characterized by deficits persisting for at least 24hours and involving the optic nerve, brain, or spinal cord, associated with regional areas of increased signal on T2-weighted images. In children, ADS may occur as a monophasic illness or as a relapsing condition, such as multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD). Almost all young people with MS have a relapsing-remitting course with clinical relapses. Important strides have been made in delineating MS from other ADS subtypes. Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and aquaporin 4-antibody-positive neuromyelitis optica spectrum disorder (AQP4-NMOSD) were once considered variants of MS; however, studies in the last decade have established that these are in fact distinct entities. Although there are clinical phenotypic overlaps between MOGAD, AQP4-NMOSD, and MS, cumulative biologic, clinical, and pathologic evidence allows discrimination between these conditions. There has been a rapid increase in the number of available disease-modifying therapies for MS and novel treatment strategies are starting to appear for both MOGAD and AQP4-NMOSD. Importantly, there are a number of both inflammatory and noninflammatory mimics of ADS in children with implications of management for these patients in terms of treatment.
More Related Videos
07:36Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
Published on: November 20, 2015
09:57Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
Published on: September 20, 2024
Related Concept Videos
Viral Meningitis
Arboviral Encephalitis
Bacterial Meningitis I: Introduction
Bacterial Meningitis II: Pathophysiology
Encephalitis l: Introduction
Encephalitis ll: Pathophysiology